Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/150433
Title: | Azithromycin for child survival: digging without getting too dirty into the differential effect on cause-specific mortality |
Author: | Madrid, Lola Bassat Orellana, Quique |
Keywords: | Tracoma Mortalitat infantil Trachoma Infant mortality |
Issue Date: | Feb-2020 |
Publisher: | Elsevier |
Abstract: | A decade ago, the astonishing and unexpected results of a trachoma trial in Ethiopia1 hinted at the exciting potential of mass azithromycin distribution to significantly reduce all-cause mortality in children by approximately 50%. In 2018, the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) multi-country study,2, 3 designed to investigate the effect of mass biannual azithromycin distribution on all-cause mortality in children aged 1–59 months in sub-Saharan African communities, corroborated these results—although with more modest and credible findings than the trachoma trial.1 The greatest reduction in all-cause mortality was observed in Niger, the site with the highest baseline mortality, where biannual mass distribution of azithromycin to children aged 1–59 months decreased all-cause mortality by 18% compared with placebo. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1016/S2214-109X(19)30558-3 |
It is part of: | Lancet Global Health, 2020, vol. 8, num. 2, p. e169-e170 |
URI: | http://hdl.handle.net/2445/150433 |
Related resource: | http://dx.doi.org/10.1016/S2214-109X(19)30558-3 |
ISSN: | 2214-109X |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
MadridL_LancetGlobHeal_2020_Comment.pdf | 38.91 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License